IL17A and neoplasm: Moreover, we found cells co-expressing IL-17A and CD4 both in the stroma and tumor regions, which accounted for 22% and 17% of all IL-17A+ cells, respectively, and for 2% and 6% of all CD4+ cells, respectively (Figure 3d).